Day One Biopharmaceuticals

Yahoo Finance • last month

Day one Biopharma general counsel sells $29k in shares

Adam Dubow, General Counsel & Secretary of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), sold 4,365 shares of common stock on August 18, 2025, at a weighted average price of $6.7671, for a total value of $29,538. The prices for these sha... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: Day One Biopharma Q2 2025 revenue growth impresses

Day One Biopharmaceuticals (NASDAQ:DAWN) reported a robust financial performance for the second quarter of 2025, driven by strong revenue growth and strategic expansions. The company’s stock experienced a 2.15% increase in aftermarket trad... Full story

Yahoo Finance • 2 months ago

Day One Biopharmaceuticals Inc (NASDAQ:DAWN) Reports Q2 2025 Earnings: Revenue Growth but Wider-Than-Expected Loss

DAY ONE BIOPHARMACEUTICALS INC (NASDAQ:DAWN [https://www.chartmill.com/stock/quote/DAWN/profile]) REPORTS Q2 2025 EARNINGS: REVENUE GROWTH BUT WIDER-THAN-EXPECTED LOSS Day One Biopharmaceuticals Inc released its second-quarter 2025 financ... Full story

Yahoo Finance • 2 months ago

Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025

BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages... Full story

Yahoo Finance • 4 months ago

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation and execution BRISBA... Full story

Yahoo Finance • 5 months ago

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term... Full story

Yahoo Finance • 5 months ago

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all age... Full story

Yahoo Finance • 7 months ago

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company to host conferenc... Full story

Yahoo Finance • 2 years ago

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

BRISBANE, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for peo... Full story

Yahoo Finance • 2 years ago

Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference

BRISBANE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for peo... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) (“Day One”) on behalf of the company’s investors. Since February 2023, shares of Day One’... Full story

Yahoo Finance • 2 years ago

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Day One Biopharmaceuticals, Inc.; Urges Day One Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determi... Full story

Yahoo Finance • 2 years ago

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

NDA for tovorafenib in relapsed or progressive pLGG accepted for FDA priority review PDUFA target action date of April 30, 2024 BRISBANE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or... Full story

Yahoo Finance • 2 years ago

12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv... Full story

Yahoo Finance • 2 years ago

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for peo... Full story

Yahoo Finance • 2 years ago

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA filing decision expected by mid-Nov... Full story

Yahoo Finance • 2 years ago

Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience

Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with high unmet need Collaboration augments Day One’s portfolio of targeted therapies in oncology BRISBANE,... Full story

Yahoo Finance • 2 years ago

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

BRISBANE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with li... Full story

Yahoo Finance • 2 years ago

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team strengthened with executive appointments in clinical development and commercialization Pre... Full story

Yahoo Finance • 2 years ago

Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Trial-in-progress poster from FIREFLY-2 andhealthcare resource use for pediatric low-grade glioma care poster to be presented Company to host co... Full story